semaglutide and masld Is the treatment for NASH we've been waiting for? Semaglutide's Efficacy in Phase 3

These dosing conditions have been used in the oral semaglutide phase 3 trials and are part of the approved label

Semaglutide is unlikely to cause liver damage and may even reduce liver fat, though it's not a treatment for liver conditions

This case highlights the need for gradual insulin tapering and close monitoring while transitioning from insulin therapy to GIP/GLP-1 receptor agonists.

Many patients experience B12 deficiencies due to dietary restrictions, absorption conditions, or underlying health issues leading to symptoms such as fatigue, brain fog, and low energy

This weight loss method has taken Hollywood by storm

By binding to GLP-1 receptors, it stimulates insulin release from the pancreas and decreases glucagon secretion